Company Raises Financial Guidance for the Full Year
WALTHAM, Mass., April 26 /PRNewswire-FirstCall/ -- Thermo Fisher
Scientific Inc. (NYSE: TMO), the world leader in serving science, reported
that revenues increased to $2.34 billion in the first quarter of 2007 (largely
as a result of the November 2006 merger with Fisher Scientific), compared with
$684 million in the 2006 quarter. GAAP diluted earnings per share (EPS) were
$.31 in 2007, versus $.28 in the year-ago period. GAAP operating income for
the 2007 quarter was $192 million, compared with $68 million in 2006, and GAAP
operating margin was 8.2%, compared with 9.9% a year ago, primarily due to
$114 million of higher intangibles amortization related to the merger with
Fisher and other acquisitions. GAAP results in 2007 also include $36 million
of pre-tax charges related to the merger.
Adjusted EPS grew 51% to $.59 in the first quarter of 2007, versus $.39 in
the 2006 quarter. Adjusted operating income increased nearly threefold in the
2007 quarter, and adjusted operating margin increased 190 basis points to
16.1%, compared with 14.2% in the 2006 period. Adjusted EPS, adjusted
operating income and adjusted operating margin are non-GAAP measures that
exclude certain items detailed later in this press release under the heading
"Use of Non-GAAP Financial Measures."
For a better year-to-year comparison of the company's quarterly
performance, we are also presenting our adjusted operating results on a pro
forma basis, as if Thermo and Fisher had been combined for all of 2006.
Revenues grew 11.5% over pro forma 2006 revenues of $2.10 billion.
Acquisitions (including those by Fisher prior to the merger) contributed 3% of
the growth, and currency translation increased revenues by 2%. Adjusted
operating income for the quarter increased 34% over pro forma 2006 results,
and adjusted operating margin expanded 270 basis points to 16.1%, compared
with pro forma adjusted operating margin of 13.4% in the 2006 period.
First Quarter Highlights
-- Revenues grew 11.5% over pro forma 2006
-- Adjusted EPS rose 51%
-- Adjusted operating income increased 34% over pro forma 2006
-- Adjusted operating margin expanded 270 basis points over pro forma 2006
-- Key new product introductions continue to expand portfolio
-- Merger integration progressing very well
"We're off to a great start in 2007, with excellent performance across the
board in our first full quarter as Thermo Fisher Scientific," said Marijn E.
Dekkers, president and chief executive officer. "These results extend our
track record of solid growth in revenues, adjusted EPS and adjusted operating
income, as well as significant expansion of our operating margins. Much of
this growth came from new products introduced within the last two years, and
now marketed under our Thermo Scientific brand. Demand remained strong for our
LTQ Orbitrap(TM) mass spectrometers, iCAP(TM) elemental analysis systems and
Niton(R) portable XRF analyzers. In addition, sales of our Mercury Freedom(TM)
air-quality monitors ramped up considerably as U.S. utilities prepare to
comply with new EPA regulations.
"I'm also pleased to report that we are right on track with the merger
integration. We are a stronger company today, with a unique combination of
portfolio breadth, customer reach and operating efficiency that sets us apart
in the marketplace. That said, we are also building upon our position as the
technology leader, which continues to be a key contributor to our growth. We
launched a number of new products during the quarter, including a new line of
Thermo Scientific SuperSignal(R) siRNA Western Blotting Kits for validated
detection of protein expression, and a new therapeutic drug-monitoring assay
for second-generation anti-epileptic treatments. At PITTCON, we showcased new
integrated workflows for a range of applications. Highlights included our
Thermo Scientific LTQ XL(TM) mass spectrometer with Electron Transfer
Dissociation (ETD) for faster, more accurate protein identification during
biomarker research, and our Thermo Scientific EQuan(TM) system for better
reliability in the analysis of environmental and drinking water samples."
Mr. Dekkers added, "We remain confident in our performance outlook for the
year, and are raising our adjusted EPS guidance based on a more favorable tax
rate. We now expect to report adjusted EPS of $2.43 to $2.53 for full-year
2007, over the $2.35 to $2.45 that we announced in December 2006. This would
lead to adjusted EPS growth of 27 to 32% over 2006. We are maintaining our
revenue guidance of $9.4 to $9.5 billion for 2007, which represents an
increase of approximately 6 to 8% over our pro forma 2006 results." (This
guidance includes the favorable impact of a full year of results from 2006
acquisitions and also takes into account the unfavorable effects of 2006
divestitures. The 2007 guidance does not factor in any future acquisitions or
divestitures, and is based on present currency exchange rates. In addition,
the adjusted EPS estimate excludes amortization expense for acquisition-
related intangible assets and certain other items detailed later in this press
release under the heading "Use of Non-GAAP Financial Measures.")
Management uses adjusted operating results to monitor and evaluate
performance of the company's business segments. Results in the following
segment information are reported on a pro forma adjusted basis for 2006, as if
Thermo and Fisher had been combined for the entire year.
Analytical Technologies Segment
Revenues in the Analytical Technologies Segment grew 15% in the first
quarter of 2007 to $1.01 billion, compared with pro forma 2006 revenues of
$872 million. Operating income increased 31% in the first quarter of 2007, and
operating margin rose to 18.9%, versus pro forma 2006 results of 16.6%.
Laboratory Products and Services Segment
In the Laboratory Products and Services Segment, revenues grew 9% in the
first quarter of 2007 to $1.42 billion, compared with pro forma 2006 revenues
of $1.30 billion. Operating income increased 37% in the first quarter of 2007,
and operating margin rose to 13.1%, versus pro forma 2006 results of 10.5%.
Use of Non-GAAP Financial Measures
In addition to the financial measures prepared in accordance with
generally accepted accounting principles (GAAP), we use certain non-GAAP
financial measures, including adjusted EPS, adjusted operating income and
adjusted operating margin, which exclude restructuring and other costs/income
and amortization of acquisition-related intangible assets. Adjusted EPS also
excludes certain other gains and losses, tax provisions/benefits related to
the previous items, benefits from tax credit carryforwards, the impact of
significant tax audits or events and discontinued operations. We exclude the
above items because they are outside of our normal operations and/or, in
certain cases, are difficult to forecast accurately for future periods. We
believe that the use of non-GAAP measures helps investors to gain a better
understanding of our core operating results and future prospects, consistent
with how management measures and forecasts the company's performance,
especially when comparing such results to previous periods or forecasts.
For example:
We exclude costs and tax effects associated with restructuring activities,
such as reducing overhead and consolidating facilities in connection with the
Fisher merger and our Kendro acquisition. We believe that the costs related to
these restructuring activities are not indicative of our normal operating
costs.
We exclude certain acquisition-related costs, including charges for the
sale of inventories revalued at the date of acquisition and professional fees
related to the merger with Fisher. We exclude these costs because we do not
believe they are indicative of our normal operating costs.
We exclude the expense and tax effects associated with the amortization of
acquisition-related intangible assets because a significant portion of the
purchase price for acquisitions may be allocated to intangible assets that
have lives of 5 to 20 years. Our adjusted EPS estimate for 2007 excludes
approximately $.86 of expense for the amortization of acquisition-related
intangible assets for acquisitions completed through the first quarter of
2007. Exclusion of the amortization expense allows comparisons of operating
results that are consistent over time for both our newly acquired and long-
held businesses and with both acquisitive and non-acquisitive peer companies.
We also exclude certain gains/losses and related tax effects, benefits
from tax credit carryforwards and the impact of significant tax audits or
events, which are either isolated or cannot be expected to occur again with
any regularity or predictability and that we believe are not indicative of our
normal operating gains and losses. We exclude gains/losses from items such as
the sale of a business or real estate, the early retirement of debt and debt
facilities and discontinued operations.
Thermo Fisher's management uses these non-GAAP measures, in addition to
GAAP financial measures, as the basis for measuring the company's core
operating performance and comparing such performance to that of prior periods
and to the performance of our competitors. Such measures are also used by
management in their financial and operating decision-making and for
compensation purposes.
The non-GAAP financial measures of Thermo Fisher's results of operations
included in this press release are not meant to be considered superior to or a
substitute for Thermo Fisher's results of operations prepared in accordance
with GAAP. Reconciliations of such non-GAAP financial measures to the most
directly comparable GAAP financial measures are set forth in the accompanying
tables. Thermo Fisher's earnings guidance, however, is only provided on an
adjusted basis. It is not feasible to provide GAAP EPS guidance because the
items excluded, other than the amortization expense, are difficult to predict
and estimate and are primarily dependent on future events, such as
acquisitions and decisions concerning the location and timing of facility
consolidations.
Conference Call
Thermo Fisher Scientific will hold its earnings conference call today,
April 26, at 9:00 a.m. Eastern time. To listen, dial 866-802-4321 within the
U.S. or 703-639-1318 outside the U.S., and use conference ID 1026515. You may
also listen to the call live on our Website, www.thermofisher.com, by clicking
on "Investors." You will find this press release, including the accompanying
reconciliation of non-GAAP financial measures and related information, in that
section of our Website under "Quarterly Results." An audio archive of the call
will be available under "Webcasts and Presentations" through Monday, May 14,
2007.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving
science, enabling our customers to make the world healthier, cleaner and
safer. With an annual revenue rate of more than $9 billion, we employ 30,000
people and serve over 350,000 customers within pharmaceutical and biotech
companies, hospitals and clinical diagnostic labs, universities, research
institutions and government agencies, as well as environmental and industrial
process control settings. Serving customers through two premier brands, Thermo
Scientific and Fisher Scientific, we help solve analytical challenges from
routine testing to complex research and discovery. Thermo Scientific offers
customers a complete range of high-end analytical instruments as well as
laboratory equipment, software, services, consumables and reagents to enable
integrated laboratory workflow solutions. Fisher Scientific provides a
complete portfolio of laboratory equipment, chemicals, supplies and services
used in healthcare, scientific research, safety and education. Together, we
offer the most convenient purchasing options to customers and continuously
advance our technologies to accelerate the pace of scientific discovery,
enhance value for customers and fuel growth for shareholders and employees
alike. Visit www.thermofisher.com.
The following constitutes a "Safe Harbor" statement under the Private
Securities Litigation Reform Act of 1995: This press release contains forward-
looking statements that involve a number of risks and uncertainties. Important
factors that could cause actual results to differ materially from those
indicated by such forward-looking statements are set forth in the Company's
Annual Report on Form 10-K for the year ended December 31, 2006, under the
caption "Risk Factors," which is on file with the Securities and Exchange
Commission and available in the "Investors" section of our Website under the
heading "SEC Filings." We also may make forward-looking statements about the
benefits of the merger of Thermo Electron and Fisher Scientific, including
statements about future financial and operating results, the new company's
plans, objectives, expectations and intentions and other statements that are
not historical facts. Important factors that could cause actual results to
differ materially from those indicated by forward-looking statements include
risks and uncertainties relating to: the risk that the businesses will not be
integrated successfully; the risk that the cost savings and any other
synergies from the transaction may not be fully realized or may take longer to
realize than expected; disruption from the transaction making it more
difficult to maintain relationships with customers, employees or suppliers;
competition and its effect on pricing, spending, third-party relationships and
revenues; the need to develop new products and adapt to significant
technological change; implementation of strategies for improving internal
growth; use and protection of intellectual property; dependence on customers'
capital spending policies and government funding policies; realization of
potential future savings from new productivity initiatives; general worldwide
economic conditions and related uncertainties; the effect of changes in
governmental regulations; the effect of exchange rate fluctuations on
international operations; the effect of laws and regulations governing
government contracts; the effect of competing with certain of our customers
and suppliers; and the effect of rapid changes in the healthcare industry.
While we may elect to update forward-looking statements at some point in the
future, we specifically disclaim any obligation to do so, even if our
estimates change and, therefore, you should not rely on these forward-looking
statements as representing our views as of any date subsequent to today.
Media Contact Information:
Lori Gorski
Phone: 781-622-1242
E-mail: lori.gorski@thermofisher.com
Website: www.thermofisher.com
Investor Contact Information:
Ken Apicerno
Phone: 781-622-1111
E-mail: ken.apicerno@thermofisher.com
Consolidated Statement of Income
(unaudited) (a)(f)(g)
Three Months Ended
March 31, % of April 1, % of
(In millions except per share 2007 Revenues 2006 Revenues
amounts)
Revenues $2,338.2 $684.3
Costs and Operating Expenses:
Cost of revenues 1,428.1 61.1% 371.7 54.3%
Selling, general and
administrative expenses 511.2 21.9% 176.9 25.9%
Amortization of acquisition-
related intangible assets 139.3 6.0% 25.6 3.8%
Research and development
expenses 59.8 2.6% 38.7 5.7%
Restructuring and other
costs, net (d) 7.4 0.3% 3.6 0.5%
2,145.8 91.8% 616.5 90.1%
Operating Income 192.4 8.2% 67.8 9.9%
Interest Income 8.9 3.5
Interest Expense (37.2) (7.7)
Other Income, Net 1.6 0.5
Income from Continuing
Operations Before Income Taxes 165.7 64.1
Provision for Income Taxes (26.9) (20.5)
Income from Continuing Operations 138.8 43.6
Income from Discontinued
Operations (net of income tax
provision of $0.1) 0.1 --
Gain on Disposal of Discontinued
Operations (net of income tax
provision of $1.9 in 2006) -- 3.3
Net Income $138.9 5.9% $46.9 6.9%
Earnings per Share from Continuing
Operations:
Basic $.33 $.27
Diluted $.31 $.26
Earnings per Share:
Basic $.33 $.29
Diluted $.31 $.28
Weighted Average Shares:
Basic 420.1 163.0
Diluted 441.1 167.0
Reconciliation of Adjusted
Operating Income and Adjusted
Operating Margin
GAAP Operating Income (a) $192.4 8.2% $67.8 9.9%
Cost of Revenues Charges (c) 36.4 1.6% -- 0.0%
Restructuring and Other Costs,
Net (d) 7.4 0.3% 3.6 0.5%
Amortization of Acquisition-
related Intangible Assets 139.3 6.0% 25.6 3.8%
Adjusted Operating Income (b) $375.5 16.1% $97.0 14.2%
Reconciliation of Adjusted Net
Income
GAAP Net Income (a) $138.9 5.9% $46.9 6.9%
Cost of Revenues Charges (c) 36.4 1.6% -- 0.0%
Restructuring and Other Costs,
Net (d) 7.4 0.3% 3.6 0.5%
Amortization of Acquisition-
related Intangible Assets 139.3 6.0% 25.6 3.8%
Provision for Income Taxes (e) (60.4) -2.6% (8.0) -1.2%
Discontinued Operations,
Net of Tax (0.1) 0.0% (3.3) -0.5%
Adjusted Net Income (b) $261.5 11.2% $64.8 9.5%
Reconciliation of Adjusted
Earnings per Share
GAAP EPS (a) $0.31 $0.28
Cost of Revenues Charges,
Net of Tax (c) 0.06 --
Restructuring and Other Costs,
Net of Tax (d) 0.01 0.03
Amortization of Acquisition-
related Intangible Assets,
Net of Tax 0.21 0.10
Discontinued Operations,
Net of Tax -- (0.02)
Adjusted EPS (b) $0.59 $0.39
Segment Data Three Months Ended
(In millions except percentage March 31, % of April 1, % of
amounts) 2007 Revenues 2006 Revenues
Revenues
Analytical Technologies $1,006.2 43.0% $504.6 73.7%
Laboratory Products and Services 1,416.5 60.6% 179.7 26.3%
Eliminations (84.5) -3.6% -- 0.0%
Consolidated Revenues $2,338.2 100.0% $684.3 100.0%
Operating Income and Operating
Margin
Analytical Technologies $189.8 18.9% $71.5 14.2%
Laboratory Products and Services 185.7 13.1% 25.5 14.2%
Subtotal Reportable Segments 375.5 16.1% 97.0 14.2%
Cost of Revenues Charges (c) (36.4) -1.6% -- 0.0%
Restructuring and Other Costs,
Net (d) (7.4) -0.3% (3.6) -0.5%
Amortization of Acquisition-
related Intangible Assets (139.3) -6.0% (25.6) -3.8%
GAAP Operating Income (a) $192.4 8.2% $67.8 9.9%
Pro Forma Data (Unaudited) (g)(h) Three Months Ended
April 1, % of
(In millions except percentage 2006 Revenues
amounts)
Pro Forma Revenues (h)
Analytical Technologies $872.2 41.6%
Laboratory Products and Services 1,299.9 62.0%
Eliminations (75.7) -3.6%
Pro Forma Combined Revenues 2,096.4 100.0%
Pre-merger Fisher Scientific Results,
Net of Eliminations (1,412.1)
GAAP Consolidated Revenues (a) $684.3
Pro Forma Operating Income and Operating
Margin (h)
Analytical Technologies $145.0 16.6%
Laboratory Products and Services 135.9 10.5%
Other/Eliminations (0.5)
Pro Forma Adjusted Combined Operating
Income (b) 280.4 13.4%
Pre-merger Fisher Scientific Results
Included Above (183.4)
Adjusted Operating Income (b) 97.0 14.2%
Cost of Revenues Charges (c) -- 0.0%
Restructuring and Other Costs, Net (d) (3.6) -0.5%
Amortization of Acquisition-related
Intangible Assets (25.6) -3.8%
GAAP Operating Income (a) $67.8 9.9%
(a) "GAAP" (reported) results were determined in accordance with U.S.
generally accepted accounting principles (GAAP).
(b) Adjusted results are non-GAAP measures and exclude certain charges to
cost of revenues (see note (c) for details); amortization of
acquisition-related intangible assets; restructuring and other costs,
net (see note (d) for details); the tax consequences of the preceding
items (see note (e) for details); and results of discontinued
operations.
(c) Reported results in 2007 include $36.4 primarily for charges for the
sale of inventories revalued at the date of acquisition.
(d) Reported results in 2007 and 2006 include restructuring and other
costs, net, consisting principally of severance, abandoned facility
and other expenses of real estate consolidation, net of net gains in
2006 on the sale of product lines and abandoned facilities.
(e) Reported provision for income taxes includes $60.4 and $8.0 of
incremental tax benefit in 2007 and 2006, respectively, for the items
in (b) through (d).
(f) Consolidated depreciation expense in 2007 and 2006 is $46.0 and $11.8,
respectively.
(g) Consolidated equity compensation expense included in both reported and
adjusted results is $13.8 and $6.1 in 2007 and 2006, respectively. The
expense was included as follows: in 2007, cost of revenues $1.3,
selling, general and administrative expenses $12.0, and research and
development expenses $0.5; and in 2006, cost of revenues $0.6,
selling, general and administrative expenses $5.2, and research and
development expenses $0.3. Equity compensation expense included in the
pro forma 2006 results is $19.5.
(h) Pro forma results combine the results of the company with the pre-
merger results of Fisher Scientific International Inc.
Condensed Consolidated Balance Sheet (unaudited)
(In millions) Mar. 31, 2007 Dec. 31, 2006
Assets
Current Assets:
Cash and cash equivalents $670.9 $667.4
Short-term investments 20.5 23.8
Accounts receivable, net 1,419.0 1,392.7
Inventories 1,180.5 1,164.5
Other current assets 455.3 411.1
Total current assets 3,746.2 3,659.5
Property, Plant and Equipment, Net 1,256.2 1,256.7
Acquisition-related Intangible Assets 7,333.2 7,511.6
Other Assets 258.3 309.4
Goodwill 8,578.0 8,525.0
Total Assets $21,171.9 $21,262.2
Liabilities and Shareholders' Equity
Current Liabilities:
Short-term obligations and current
maturities of long-term obligations $167.4 $483.3
Other current liabilities 1,629.1 1,669.0
Total current liabilities 1,796.5 2,152.3
Other Long-term Liabilities 2,960.3 3,017.4
Long-term Obligations 2,182.4 2,180.7
Total Shareholders' Equity 14,232.7 13,911.8
Total Liabilities and Shareholders' Equity $21,171.9 $21,262.2
SOURCE Thermo Fisher Scientific Inc.
-0- 04/26/2007
/CONTACT: media, Lori Gorski, +1-781-622-1242,
lori.gorski@thermofisher.com, or investors, Ken Apicerno, +1-781-622-1111,
ken.apicerno@thermofisher.com, both of Thermo Fisher Scientific Inc./
/Company News On-Call: http://www.prnewswire.com/comp/877850.html /
/Web site: http://www.thermofisher.com /
(TMO)
CO: Thermo Fisher Scientific Inc.
ST: Massachusetts
IN: CPR EPM ENV
SU: CCA ERN
RF-GF
-- NETH023 --
5276 04/26/2007 06:00 EDT http://www.prnewswire.com
